UBS Group AG Boosts Stake in Contineum Therapeutics, Inc. $CTNM

UBS Group AG lifted its holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) by 191.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 199,389 shares of the company’s stock after buying an additional 130,885 shares during the quarter. UBS Group AG owned 0.68% of Contineum Therapeutics worth $2,279,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Contineum Therapeutics in the fourth quarter valued at approximately $43,000. Strs Ohio purchased a new stake in shares of Contineum Therapeutics in the first quarter valued at approximately $27,000. Bank of America Corp DE boosted its stake in shares of Contineum Therapeutics by 500.0% in the third quarter. Bank of America Corp DE now owns 7,236 shares of the company’s stock valued at $85,000 after buying an additional 6,030 shares in the last quarter. Qube Research & Technologies Ltd purchased a new stake in shares of Contineum Therapeutics in the second quarter valued at approximately $43,000. Finally, Marex Group plc purchased a new stake in shares of Contineum Therapeutics in the second quarter valued at approximately $45,000.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Morgan Stanley lifted their price objective on Contineum Therapeutics from $14.00 to $16.00 and gave the stock an “equal weight” rating in a report on Thursday, May 14th. Robert W. Baird lifted their price objective on Contineum Therapeutics from $14.00 to $20.00 and gave the stock an “outperform” rating in a report on Friday, March 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Contineum Therapeutics in a report on Monday, April 20th. Finally, Wall Street Zen raised Contineum Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Contineum Therapeutics has an average rating of “Moderate Buy” and an average price target of $20.00.

Contineum Therapeutics Stock Down 1.9%

NASDAQ CTNM opened at $13.44 on Thursday. Contineum Therapeutics, Inc. has a fifty-two week low of $3.35 and a fifty-two week high of $16.33. The stock has a market cap of $502.52 million, a price-to-earnings ratio of -6.89 and a beta of 0.89. The business has a fifty day moving average of $13.24 and a 200-day moving average of $12.86.

Contineum Therapeutics (NASDAQ:CTNM) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.16. As a group, analysts anticipate that Contineum Therapeutics, Inc. will post -1.79 EPS for the current year.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.